<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627116</url>
  </required_header>
  <id_info>
    <org_study_id>ZK-TEK-201905</org_study_id>
    <nct_id>NCT04627116</nct_id>
  </id_info>
  <brief_title>An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese Volunteers</brief_title>
  <official_title>A Multiple-Dose, Safety and Tolerability、PK/PD Study of Tecarfarin in Healthy Chinese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The subjects will be admitted to the Phase I Clinical Research Center on day -1. Subjects&#xD;
      received once-daily doses of Tecarfarin for up to 14 days.Subjects can leave the Phase I&#xD;
      Clinical Research Center on the day 21.And returned to the research center for follow-up on&#xD;
      the day 28 and 35.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 19, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study was to evaluate the safety and tolerability of Tecarfarin when administered as rising multiple oral doses to healthy Chinese volunteers.</measure>
    <time_frame>doses of Tecarfarin for up to 14 days.</time_frame>
    <description>Subjects received once-daily doses of Tecarfarin for up to 14 days.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Chinese Volunteers</condition>
  <arm_group>
    <arm_group_label>Tecarfarin 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tecarfarin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tecarfarin 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tecarfarin 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tecarfarin</intervention_name>
    <description>Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.</description>
    <arm_group_label>Tecarfarin 10mg</arm_group_label>
    <arm_group_label>Tecarfarin 20mg</arm_group_label>
    <arm_group_label>Tecarfarin 30mg</arm_group_label>
    <arm_group_label>Tecarfarin 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) the subjects were fully aware of the purpose, nature, methods and possible adverse&#xD;
        reactions of the trial, voluntarily act as subjects, and sign an informed consent form&#xD;
        before the commencement of any research process.&#xD;
&#xD;
        2）Healthy volunteers between the ages of 18 to 50 years old (inclusive). 3）Weight: male ≥&#xD;
        50.0kg, female ≥ 45.0kg; Body Mass Index (BMI) ≥19 and ≤ 24 kg/m2.&#xD;
&#xD;
        4) The physical examination, vital sign measurements, clinical laboratory assessments&#xD;
        hematology, clinical chemistry, or urinalysis, etc.) and 12-lead ECG were judged normal, or&#xD;
        abnormal without clinical significance by the investigators.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Positive test results for HIV, syphilis antibody, hepatitis B surface antigen (HBsAg),&#xD;
        or hepatitis C antibody (HCV Ab) at Screening.&#xD;
&#xD;
        2) Dysphagia or documented history of any gastrointestinal disorders that affect drug&#xD;
        absorption.&#xD;
&#xD;
        3) Subjects with difficulty in venipuncture, those who cannot tolerate venipuncture, and&#xD;
        those who have a history of needlesickness and bloodsickness.&#xD;
&#xD;
        4) Positive tests for urine drugs of abuse at Screening or a history of drug or alcohol&#xD;
        abuse/dependence.&#xD;
&#xD;
        5) Use of tobacco products 3 months before screening. 6）Heavy tea, coffee and / or&#xD;
        caffeinated drinks (more than 8 cups, 1 cup = 250 mL) drinker per day within 3 months prior&#xD;
        to screening.&#xD;
&#xD;
        7）Subjects who drunk frequently within 6 months prior to screening (intake of more than 14&#xD;
        units of alcohol per week. A unit is 360 mL beer, 45 mL of 40% liquor or 150 mL wine).&#xD;
&#xD;
        8）Any out-of-normal-range PT, aPTT, TT, FIB,INR, protein C, protein S or coagulation&#xD;
        factors II, VII, X at screening.&#xD;
&#xD;
        9）History of cardiovascular, renal, pulmonary, nervous system, liver and/or endocrine&#xD;
        disease.&#xD;
&#xD;
        10）Documented history of bleeding diathesis, coagulopathy, or inherited disorders of&#xD;
        coagulation.&#xD;
&#xD;
        11）Evidence of active bleeding, including but not limited to gastrointestinal bleeding&#xD;
        (hematemesis, hematochezia, positive fecal occult blood), urinary tract bleeding, mucosal&#xD;
        bleeding (gingival, epistaxis) and unexplained subcutaneous bleeding or ecchymosis.&#xD;
&#xD;
        12）Participation in a previous clinical trial within 3 months prior to Screening.&#xD;
&#xD;
        13）Clinically significant surgical procedure within 4 weeks prior to Screening or planned&#xD;
        to undergo surgery during the study period.&#xD;
&#xD;
        14) Clinically significant blood loss or blood donation &gt; 550 ml within 3 months prior to&#xD;
        Screening.&#xD;
&#xD;
        15）Taking any medication 14 days prior to Screening. 16）Known allergy or hypersensitivity&#xD;
        to warfarin or the investigational product.&#xD;
&#xD;
        17）Pregnancy or Lactation. 18）Female subjects cannot avoid menstruation during&#xD;
        administration. 19）subjects of childbearing age are not guaranteed to have no fertility&#xD;
        plan, sperm donation, egg donation plan and voluntary use of non-drug contraceptive&#xD;
        measures (including subcutaneous injection of contraceptive, contraceptive injections,&#xD;
        subcutaneous implantation of contraceptives, local contraceptives such as spermicide, etc.)&#xD;
        from two weeks before screening to 6 months after the end of the trial.&#xD;
&#xD;
        20）Investigator would make the subject unsuitable for the study or put them at additional&#xD;
        risks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Second Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>November 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 8, 2020</last_update_submitted>
  <last_update_submitted_qc>November 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

